Taysha Gene Therapies (TSHA)
(Real Time Quote from BATS)
$2.78 USD
+0.04 (1.46%)
Updated Aug 6, 2025 03:41 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Taysha Gene Therapies, Inc. has a market cap of $588.17M, which represents its share price of $2.74 multiplied by its outstanding shares number of 214.66M. As a small-cap company, TSHA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TSHA 2.78 +0.04(1.46%)
Will TSHA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Other News for TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA ...
Taysha Gene Therapies (TSHA) Receives 'Buy' Rating from B of A Securities | TSHA Stock News
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News
Taysha Gene Therapies initiated with bullish view at BofA, here's why
Taysha Gene Therapies initiated with bullish view at BofA